The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection - Suramin inhibits EV71 infection in vitro and in vivo

Emerging Microbes and Infections

Volumn 3, Issue 9, 2014, Pages e62-

  Ren, Peijun ^a,b,c   Zou, Gang ^a   Bailly, Benjamin ^a,d   Xu, Shanshan ^a   Zeng, Mei ^e   Chen, Xinsheng ^f   Shen, Liang ^f   Zhang, Ying ^g   Guillon, Patrice ^d   Arenzana Seisdedos, Fernando ^c   Buchy, Philippe ^h   Li, Jian ^f   Von Itzstein, Mark ^d   Li, Qihan ^g   Altmeyer, Ralf ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d GRIFFITH UNIVERSITY   (Australia)

^e CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

^f WUXI APPTEC   (China)

^g INSTITUTE OF MEDICAL BIOLOGY   (China)

^h INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

Anti viral; Drug discovery; Enterovirus 71; Foot and mouth disease; Hand; Suramin

Indexed keywords

NAPHTALENTRISULONIC ACID; NAPHTHALENE DERIVATIVE; SURAMIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLEARANCE AT STEADY-STATE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS CAPSID; VIRUS INHIBITION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

HUMAN ENTEROVIRUS 71; MACACA MULATTA; MIRIDAE; MUS;

EID: 84931264421     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.60     Document Type: Article

References (50)

1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778-790.
2. Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 2009; 7: 735-742.
3. World Health Organization. Hand, foot and mouth disease (HFMD). WHO: Manila, 2013. Available at http://www.wpro.who.int/emerging-diseases/HFMD/en/.
4. Yang F, Ren L, Xiong Z et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 2009; 47: 2351-2352.
5. Mirand A, Schuffenecker I, Henquell C et al. Phylogenetic evidence for a recent spread of two populations of human enterovirus 71 in European countries. J Gen Virol 2010; 91: 2263-2277.
6. Zeng M, Pu D, Mo X et al. Children of rural-to-urban migrant workers in China are at a higher risk of contracting severe hand, foot and mouth disease and EV71 infection: a hospital-based study. Emerg Microbes Infect 2013; 2: e72.
7. Xing W, Liao Q, Viboud CC et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 2014; 14: 308-318.
8. Zeng M, El Khatib NF, Tu S et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol 2012; 53: 285-289.
9. Bessaud M, Razafindratsimandresy R, Nougairède A et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human Enterovirus 71 isolates reveal a wide genetic diversity. PLoS ONE 2014; 9: e90624.
10. Khanh TH, Sabanathan S, Thanh TT et al. Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg Infect Dis 2012; 18: 2002-2005.
11. Yamayoshi S, Yamashita Y, Li J et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009; 15: 798-801.
12. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human Pselectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 2009; 15: 794-797.
13. Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 2013; 87: 3335-3347.
14. Tan CW, Poh CL, Sam IC, Chan YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 2013; 87: 611-620.
15. Du N, Cong H, Tian H et al. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol 2014; 88: 5816-5833.
16. Ooi MH, Wong SC, Lewthwaite P, CardosaMJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9: 1097-1105.
17. Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci USA 2013; 110: 5463-5467.
18. de Palma AM, Vliegen I, de Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev 2008; 28: 823-884.
19. Zhang X, Song Z, Qin B et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 2013; 97: 264-269.
20. Lu G, Qi J, Chen Z et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 2011; 85: 10319-10331.
21. Zhang G, Zhou F, Gu B et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol 2012; 157: 669-679.
22. Pourianfar HR, Poh CL, Fecondo J, Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res 2012; 169: 22-29.
23. Yorke W. The treatment of Kala-Azar by "Bayer 205". Br Med J 1923; 1: 370.
24. Faust SN, Woodrow CJ, Patel S et al. Sleeping sickness in brothers in london. Pediatr Infect Dis J 2004; 23: 879-881.
25. Lam ET, Au JL, Otterson GA et al. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 66: 1019-1029.
26. Jentsch KD, Hunsmann G, Hartmann H, Nickel P. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J Gen Virol 1987; 68: 2183-2192.
27. Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Suramin prevents duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1993; 37: 1539-1542.
28. Xu W, Liu CF, Yan L et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012; 9: 8.
29. Liu J, Yang Y, Xu Y, Ma C, Qin C, Zhang L. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J 2011; 8: 483.
30. Zhang Y, Cui W, Liu L et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 2011; 91: 1337-1350.
31. Liu L, Zhang Y, Wang J et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013; 8: e54451.
32. Haselhorst T, Garcia JM, Islam T et al. Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew Chem Int Ed Engl 2008; 47: 1910-1912.
33. Haselhorst T, Fleming FE, Dyason JC et al. Sialic acid dependence in rotavirus host cell invasion. Nat Chem Biol 2009; 5: 91-93.
34. Nagata N, Iwasaki T, Ami Y et al. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 2004; 85: 2981-2989.
35. Liu L, Zhao H, Zhang Y et al. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 2011; 412: 91-100.
36. Vanchieri C, Butler AS, Knutsen A. Addressing the barriers to pediatric drug development: workshop summary. Washington, DC: The National Academies Press, 2008.
37. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448: 645-646.
38. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc 2011; 86: 561-583.
39. Khaw M, Panosian CB. Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev 1995; 8: 427-439.
40. Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: what did we learn? Invest New Drugs 2002; 20: 209-219.
41. Scher HI, Jodrell DI, Iversen JM et al. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 1992; 52: 64-70.
42. Bowden CJ, Figg WD, Dawson NA et al. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 1996; 39: 1-8.
43. Lustberg MB, Pant S, Ruppert AS et al. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol 2012; 70: 49-56.
44. Nagata N, Shimizu H, Ami Y et al. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 2002; 67: 207-216.
45. Altmeyer R. Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des 2004; 10: 3701-3712.
46. Vercauteren K, Leroux-Roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. Future Virol 2012; 7: 547-561.
47. Curreli F, Choudhury S, Pyatkin I et al. Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem 2012; 55: 4764-4775.
48. Webster AD. Pleconaril - an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol 2005; 32: 1-6.
49. Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 2008; 89: 2518-2530.
50. Zeitlinger MA, Derendorf H, Mouton JW et al. Protein binding: do we ever learn? Antimicrob Agents Chemother 2011; 55: 3067-3074.